Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone

Bernard Charbonnel, Avraham Karasik, Ji Liu, Mei Wu, Gary Meininger*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

702 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science